Thermo Fisher Scientific Complement C9 Monoclonal Antibody (22)

Applications

Tested Dilution

Publications

Western Blot (WB)

Assay-dependent

-

Immunohistochemistry (IHC)

-

View 1 publication 1 publication

Immunohistochemistry (Paraffin) (IHC (P))

1:100

-

ELISA (ELISA)

10 µg/mL

-

Product Specifications

Species Reactivity

Human

Published species

Human

Host/Isotype

Mouse / IgG1, kappa

Class

Monoclonal

Type

Antibody

Clone

22

Immunogen

Complement component C9. if (typeof window.$mangular === undefined || !window.$mangular) { window.$mangular = {}; } $mangular.antigenJson = \[{targetFamily:Complement C9,uniProtId:P02748-1,ncbiNodeId:9606,antigenRange:1-559,antigenLength:559,antigenImageFileName:ABS_004-22-02_Complement_C9_P02748-1_House_mouse.svg,antigenImageFileNamePDP:ABS_004-22-02_Complement_C9_P02748-1_House_mouse_PDP.jpeg,sortOrder:1}\]; $mangular.isB2BCMGT = false; $mangular.isEpitopesModalImageMultiSizeEnabled = true;

View immunogen .st0{fill:#FFFFFF;} .st1{fill:#1E8AE7;}

Conjugate

Unconjugated Unconjugated Unconjugated

Form

Liquid

Concentration

1.03 mg/mL

Purification

Protein A

Storage buffer

PBS, pH 7.4

Contains

15mM sodium azide

Storage conditions

4° C, store in dark

Shipping conditions

Ambient (domestic); Wet ice (international)

RRID

AB_1073845

Product Specific Information

ABS 004-22-02 is specific for complement factor C9.

ABS 004-22-02 has been successfully used in ELISA and Western blot procedures. ABS 004-22-02 recognizes C9 in human serum diluted 1:50 in Tris buffer (20 mM Tris-base, 1 mM MgCl2, 1 mM CaCl2 and 140 mM NaCl) and incubated for 2 hours at 37°C using a human IgM coated (10 µg/mL overnight at 4°C, blocked with PBS 7.2 + 1% BSA for 1 hour) ELISA plate.

NOTE: Concentration is lot-dependent and can vary from 0.85-1.15 mg/mL

Target Information

C5b-9 membrane attack complexes are assembled from five precursor molecules in the serum. Proteolytic cleavage of C5 by C5 convertase generates C5b which initiates assembly of the C5b-9 complex. The last step of C5b-9 complex formation involves polymerization of C9 which accompanies insertion of the complex into the cell membrane. During formation of C5b-8 and C9 polymerization, neoantigens are generated which are unique to the C5b-9 complex and are not present on any of the individual native complex components. The complement regulatory proteins CD59 and complement S-protein can both prevent C5b-9 insertion into the cell membrane. The formed SC5b-9 complex is unable to attach to cells and is cytolytically inactive. C5b-9 is involved in the progression of chronic proteinuric renal disease by mediating continuous tubulointerstitial damage. Early tubulointerstitial injury in the remnant kidney can be improved when C5b-9 complex forming is abrogated.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.